Europe
Munich/ Martinsried Medigene AG, a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies, announces that Medigene’s researchers presented clinical immune monitoring data obtained during the first year of treatment from the ongoing Phase I/II clinical trial with Medigene’s DC vaccine for the treatment of acute myeloid leukemia at the 61st ASH Annual Meeting.
Pharma and biotech companies strengthen their leadership teams and boards with this week’s hires.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
AstraZeneca and Daiichi Sankyo presented positive data from their Phase II single-arm DESTINY-Breast01 trial of trastuzumab deruxtecan (DS-8201) in HER2-positive metastatic breast cancer patients who received two or more previous HER-2 targeted regimens.
The U.S. Food and Drug Administration issued a warning letter to the company for misbranding its opioid addiction medication Vivitrol in promotional materials.
Companies from across the globe provide updates to their business and pipelines.
At the six-year mark, 90.6% of patients in the Perjeta cohort have not had breast cancer return, compared to 87.8% in the placebo arm. This comes to an absolute benefit of 2.8%.
Sanofi believes that sutimlimab, a novel investigational C1s inhibitor, has the potential to be the first approved treatment for cold agglutinin disease, a serious and chronic rare blood disorder.
A new model in the Sona microscopy cameras range – The World’s Most Sensitive Back-illuminated sCMOS Cameras
Oxford Gene Technology, A Sysmex Group Company, has developed a breakthrough targeted NGS panel for constitutional cytogenetics research.
PRESS RELEASES